Omeros (OMER) Cash from Operations (2010 - 2026)
Omeros (OMER) posted Cash from Operations of 14506000.0 for Q1 2026, up 63.59% sequentially from 39842000.0 in Q4 2025, and up 59.53% YoY from 9093143.03 in Q1 2025.
Powered by 
Analysis
Omeros (OMER) Cash from Operations (2010 - 2026) Analysis & Trends
Omeros has reported Cash from Operations for 17 years, with the latest figure at 14506000.0 in Q1 2026.
- Quarterly Cash from Operations rose 59.53% year-over-year to 14506000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 94759000.0 (up 33.67% YoY) and the FY2025 annual result came in at 116094000.0, up 21.98% from the prior year.
- Cash from Operations climbed to 14506000.0 in Q1 2026 per OMER's latest filing, from 39842000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 174539000.0 in Q1 2023 and troughed at 45985000.0 in Q2 2024.
- A 5-year average of 17127058.82 and a median of 28980000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations soared 1248.81% in 2023, then tumbled 123.94% in 2024.
- Over 5 years, Cash from Operations stood at 25382000.0 in 2022, then sank by 37.2% to 34825000.0 in 2023, then climbed by 16.78% to 28980000.0 in 2024, then plunged by 37.48% to 39842000.0 in 2025, then surged by 63.59% to 14506000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 14506000.0, 39842000.0, and 18473000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Omeros | 1.38 Bn | 1.38 Bn | 27.73 Mn | 4.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.15 Mn |
| Mar 31, 2026 | -14.51 Mn |
| Dec 31, 2025 | -39.79 Mn |
| Sep 30, 2025 | -18.52 Mn |
| Jun 30, 2025 | -21.94 Mn |
| Mar 31, 2025 | -35.84 Mn |
| Dec 31, 2024 | -28.98 Mn |
| Sep 30, 2024 | -32.06 Mn |
| Jun 30, 2024 | -45.99 Mn |
| Mar 31, 2024 | -41.78 Mn |
| Dec 31, 2023 | -34.83 Mn |
| Sep 30, 2023 | -32.65 Mn |
| Jun 30, 2023 | -32.34 Mn |
| Mar 31, 2023 | 174.54 Mn |
| Dec 31, 2022 | -25.38 Mn |
| Sep 30, 2022 | -26.44 Mn |
| Jun 30, 2022 | -19.47 Mn |
| Mar 31, 2022 | -15.19 Mn |
| Dec 31, 2021 | -18.22 Mn |
| Sep 30, 2021 | -23.66 Mn |